Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07477756 · ClinicalTrials.gov registry record
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,247
- Enrollment target
NCT07477756: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07477756 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,247 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07477756 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,247 participants
- Enrollment target
Study Summary
The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.
Primary Outcome
Patient characteristics included: * Age * Race * Marital status * Insurance status * Practice type * Physician specialty * Geographic region * Have a Gleason score ≤1 year of index * Gleason score (\<7, ≥7) * Have a prostate-specific antigen (PSA) test ≤1 year of index * PSA level (elevated, normal, unknown)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,247 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2025-03-14 |
What the finished NCT07477756 record still lists
NCT07477756 is an observational study that tracks outcomes without assigning an intervention. Its 1,247 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07477756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07477756 about?
NCT07477756 is a clinical study titled "A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients". The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.
What is the current status of trial NCT07477756?
This trial is currently completed. The enrollment target is 1,247 participants. The study started on 2024-09-04. Estimated completion is 2025-03-14.
Who is sponsoring clinical trial NCT07477756?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI